Press Releases FDA Must Promptly Withdraw Approval of Medication for Prevention of Preterm Birth October 18, 2022
In the News STAT Opinion: NEJM, other journals: provide more transparency about conflicts of interest or don’t publish conflicted articles May 19, 2022
Press Releases Statement: FDA’s Reckless Decision to Approve Ineffective Alzheimer’s Disease Drug Causing Financial Pain for All Medicare Part B Beneficiaries November 15, 2021
Press Releases Statement: Inspector General’s Decision To Investigate FDA’s Inappropriately Close Collaboration With Biogen on the Alzheimer’s Disease Drug Aducanumab Is Long Overdue August 4, 2021
Press Releases Letter: Woodcock Must Be Investigated as Part of IG’s Probe Into Aducanumab’s Approval July 13, 2021
Press Releases Statement: Woodcock’s Role in Aducanumab’s Approval Must be Investigated as Part of IG Probe July 9, 2021
Press Releases Letter: Acting FDA Commissioner Woodcock, Other Top Officials Must Resign Following Indefensible Aducanumab Approval June 16, 2021